Tianjin Pharmaceutical Da Ren Tang Provides Update on Planned Upstream Share Transfer

SGX Filings

Sep 24

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited stated on Sep, 24 2026 that its controlling shareholder, Tianjin Pharmaceutical Holdings Co., Ltd. (TPH), has confirmed the formal listing of a planned disposal involving 100% of Shanghai Liuliguang Medical Development Co., Ltd. on the Shanghai United Assets and Equity Exchange.

The information disclosure for the proposed transfer began on Sep, 24 2026 and is scheduled to end on Oct, 29 2026. The sale concerns the entire equity interests held by SIIC Shanghai (Holdings) Co., Ltd. and Shanghai SIIC Investment Development Co., Ltd. in Liuliguang Medical, which is an upstream shareholder in TPH’s ownership chain.

Current ownership details provided by the company are: • TPH owns about 43.091% of Tianjin Pharmaceutical Da Ren Tang. • Jinhushen Biological Medical Science and Technology Co., Ltd. holds 67% of TPH, while Tianjin Guoyu Enterprise Management Co., Ltd. owns the remaining 33%. • Liuliguang Medical controls 35% of Jinhushen. • SIIC Shanghai (Holdings) Co., Ltd. and Shanghai SIIC Investment Development Co., Ltd. respectively own 51% and 49% of Liuliguang Medical.

Tianjin Pharmaceutical Da Ren Tang said it will monitor the process and release further updates as necessary. The firm cautioned investors that there is no certainty the transaction will be completed.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/news/1191096753"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191096753\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1191096753?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-24 18:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191096753","market":"sg","top_or_hot":-1,"title":"Tianjin Pharmaceutical Da Ren Tang Provides Update on Planned Upstream Share Transfer","media":"SGX Filings","content":"<p>Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited stated on Sep, 24 2026 that its controlling shareholder, Tianjin Pharmaceutical Holdings Co., Ltd. (TPH), has confirmed the formal listing of a planned disposal involving 100% of Shanghai Liuliguang Medical Development Co., Ltd. on the Shanghai United Assets and Equity Exchange.</p>\n<p>The information disclosure for the proposed transfer began on Sep, 24 2026 and is scheduled to end on Oct, 29 2026. The sale concerns the entire equity interests held by SIIC Shanghai (Holdings) Co., Ltd. and Shanghai SIIC Investment Development Co., Ltd. in Liuliguang Medical, which is an upstream shareholder in TPH’s ownership chain.</p>\n<p>Current ownership details provided by the company are:  \n• TPH owns about 43.091% of Tianjin Pharmaceutical Da Ren Tang.  \n• Jinhushen Biological Medical Science and Technology Co., Ltd. holds 67% of TPH, while Tianjin Guoyu Enterprise Management Co., Ltd. owns the remaining 33%.  \n• Liuliguang Medical controls 35% of Jinhushen.  \n• SIIC Shanghai (Holdings) Co., Ltd. and Shanghai SIIC Investment Development Co., Ltd. respectively own 51% and 49% of Liuliguang Medical.</p>\n<p>Tianjin Pharmaceutical Da Ren Tang said it will monitor the process and release further updates as necessary. The firm cautioned investors that there is no certainty the transaction will be completed.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tianjin Pharmaceutical Da Ren Tang Provides Update on Planned Upstream Share Transfer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTianjin Pharmaceutical Da Ren Tang Provides Update on Planned Upstream Share Transfer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1083912268\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">SGX Filings </p>\n<p class=\"h-time\">2026-09-24 18:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited stated on Sep, 24 2026 that its controlling shareholder, Tianjin Pharmaceutical Holdings Co., Ltd. (TPH), has confirmed the formal listing of a planned disposal involving 100% of Shanghai Liuliguang Medical Development Co., Ltd. on the Shanghai United Assets and Equity Exchange.</p>\n<p>The information disclosure for the proposed transfer began on Sep, 24 2026 and is scheduled to end on Oct, 29 2026. The sale concerns the entire equity interests held by SIIC Shanghai (Holdings) Co., Ltd. and Shanghai SIIC Investment Development Co., Ltd. in Liuliguang Medical, which is an upstream shareholder in TPH’s ownership chain.</p>\n<p>Current ownership details provided by the company are:  \n• TPH owns about 43.091% of Tianjin Pharmaceutical Da Ren Tang.  \n• Jinhushen Biological Medical Science and Technology Co., Ltd. holds 67% of TPH, while Tianjin Guoyu Enterprise Management Co., Ltd. owns the remaining 33%.  \n• Liuliguang Medical controls 35% of Jinhushen.  \n• SIIC Shanghai (Holdings) Co., Ltd. and Shanghai SIIC Investment Development Co., Ltd. respectively own 51% and 49% of Liuliguang Medical.</p>\n<p>Tianjin Pharmaceutical Da Ren Tang said it will monitor the process and release further updates as necessary. The firm cautioned investors that there is no certainty the transaction will be completed.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"T14.SI","symbol_name":"达仁堂","start_time":0,"source_url":"","article_id":"1191096753","we_media_id":"1083912268","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191096753","pubTimestamp":1790244439,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"SGX Filings","introduction":"Fastest News on SGX Filings ","home_visible":1,"id":"1083912268","head_image":"https://community-static.tradeup.com/news/57d1beae95c40ebe9f2698a436562e39"},"summary":"Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited stated on Sep, 24 2026 that its controlling shareholder, Tianjin Pharmaceutical Holdings Co., Ltd. (TPH), has confirmed the formal listing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"T14.SI":"达仁堂"},"translate_title":"天津医药大仁堂提供上游股份转让计划的最新情况","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"T14.SI":1},"content_text":"Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited stated on Sep, 24 2026 that its controlling shareholder, Tianjin Pharmaceutical Holdings Co., Ltd. (TPH), has confirmed the formal listing of a planned disposal involving 100% of Shanghai Liuliguang Medical Development Co., Ltd. on the Shanghai United Assets and Equity Exchange.\nThe information disclosure for the proposed transfer began on Sep, 24 2026 and is scheduled to end on Oct, 29 2026. The sale concerns the entire equity interests held by SIIC Shanghai (Holdings) Co., Ltd. and Shanghai SIIC Investment Development Co., Ltd. in Liuliguang Medical, which is an upstream shareholder in TPH’s ownership chain.\nCurrent ownership details provided by the company are:  \n• TPH owns about 43.091% of Tianjin Pharmaceutical Da Ren Tang.  \n• Jinhushen Biological Medical Science and Technology Co., Ltd. holds 67% of TPH, while Tianjin Guoyu Enterprise Management Co., Ltd. owns the remaining 33%.  \n• Liuliguang Medical controls 35% of Jinhushen.  \n• SIIC Shanghai (Holdings) Co., Ltd. and Shanghai SIIC Investment Development Co., Ltd. respectively own 51% and 49% of Liuliguang Medical.\nTianjin Pharmaceutical Da Ren Tang said it will monitor the process and release further updates as necessary. The firm cautioned investors that there is no certainty the transaction will be completed.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}